Novo Nordisk
Pharmaceuticals · Denmark
Novo Nordisk is a Danish healthcare company that makes and sells medicines for obesity, diabetes and rare diseases, led by its semaglutide drugs Ozempic and Wegovy and by insulin.
What makes it different
US rebates and discounts take more than half of gross sales.
DKK 394.6BUS rebates, discounts and returnsFY2025
List prices in the US are heavily reduced by insurers, wholesalers and Medicaid before Novo books its sales.
How big it is
How big is Novo Nordisk?
DKK 309.1BNet salesFY2025
45.6MPatients reachedFY2025
69,505EmployeesFY2025
How it makes money FY2025
Diabetes and obesity care.
- Diabetes careDKK 207.1B
- Obesity careDKK 82.3B
- Rare diseaseDKK 19.6B
How the business works
From lab to patient.
- 1Semaglutide and successors
- 2In-house API and pens
- 3Wholesalers and self-pay
Owning the plants that make the drug and its pen is as strategic as inventing it.
Brands and businesses
More than Novo Nordisk.
Who owns it
- Other shareholders71.4%
- Novo Holdings A/S (owned by the Novo Nordisk Foundation)28.1%
CEO: Maziar Mike Doustdar
Who it competes with
Key moments
- 1923Nordisk starts making insulin
- 1925Novo Industri is founded
- 1989Nordisk Gentofte and Novo Industri merge
- 2-05Ozempic approved in the US
- 6-04Wegovy approved for obesity in the US
Sources
Every number on this page comes from Novo Nordisk's own reports.
Full profile
The rest of the story is in the app.
What Novo Nordisk tracks28 metrics
Patients reached
Countries with Wegovy available
Global GLP-1 volume market share
Results, quarter by quarterwith a chart
Revenue
Profit
Margin
Where the money comes from5 regions
US Operations
EUCAN
Emerging Markets
The full timeline20 moments
2019
2025
2026
Novo Nordisk vs Eli Lillyside by side
Revenue
Profit
People
Point your phone at a logo.
See the company behind it.
The full story in 12 chapters · compare any two companies · 335 companies, and any other on request.
Download on the App Store
